<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib16">
 <label>16</label>
 <element-citation publication-type="journal" id="ref0085">
  <person-group person-group-type="author">
   <name>
    <surname>Smith</surname>
    <given-names>P.F.</given-names>
   </name>
   <name>
    <surname>Ogundele</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Forrest</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Wilton</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Salzwedel</surname>
    <given-names>K.</given-names>
   </name>
  </person-group>
  <article-title>Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′, 3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <volume>51</volume>
  <year>2007</year>
  <fpage>3574</fpage>
  <lpage>3581</lpage>
  <pub-id pub-id-type="pmid">17638699</pub-id>
 </element-citation>
</ref>
